1.
使用NSAIDs组与未使用NSAIDs组的基线特征和后续治疗
Baseline characteristics and Subsequent therapy of patients in both groups with and without NASIDS
| Characteristics | Before matching | After matching | |||||
| NASIDS(+) (n=36) | NASIDS(-) (n=179) | P | NASIDS(+)(n=33) | NASIDS(-)(n=78) | P | ||
| Values are expressed as n(%); (+): The drug has been used; (-): The drugs have not been used; ECOG PS: Eastern cooperative oncology group performance status; BCLC: Barcelona clinic liver cancer; TACE: Transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; AFP: α-fetoprotein. | |||||||
| Age(≥65 years) | 2(5.6) | 30(16.8) | 0.085 | 2(6.1) | 12(15.4) | 0.224 | |
| Male | 32(88.9) | 157(87.7) | 1.000 | 67(85.9) | 30(90.9) | 0.549 | |
| History | |||||||
| Hepatitis B | 32(88.9) | 151(84.4) | 0.486 | 29(87.9) | 60(76.9) | 0.186 | |
| Cirrhosis | 17(47.2) | 109(60.9) | 0.129 | 16(48.5) | 48(61.5) | 0.203 | |
| Drink | 12(33.3) | 37(20.7) | 0.098 | 11(33.3) | 21(26.9) | 0.496 | |
| Lymph node metastasis | 11(30.6) | 75(41.9) | 0.205 | 10(30.3) | 30(38.5) | 0.413 | |
| Extrahepatic metastasis | 10(27.8) | 73(40.8) | 0.144 | 8 (24.2) | 30(38.5) | 0.149 | |
| Tumor thrombus | 16(44.4) | 80(44.7) | 0.978 | 13(39.4) | 30(38.5) | 0.927 | |
| BCLC stage | |||||||
| A | 3(8.3) | 6(3.4) | 0.894 | 3(9.1) | 2(2.6) | 0.239 | |
| B | 5 (13.9) | 38(21.2) | 5 (15.2) | 20(25.6) | |||
| C | 28(77.8) | 135(75.4) | 25(75.8) | 56(71.8) | |||
| ECOG PS | 0.721 | 1.000 | |||||
| 0-1 | 33(91.7) | 167(93.3) | 30(90.9) | 72(92.3) | |||
| ≥2 | 3(8.3) | 12(6.7) | 3(9.1) | 6(7.7) | |||
| Child-Pugh | 0.622 | 0.476 | |||||
| A | 30(83.3) | 142(79.3) | 27(81.8) | 59(75.6) | |||
| B | 6 (16.7) | 37(20.6) | 6 (18.2) | 19(24.4) | |||
| Prior therapy | |||||||
| Targeted Therapy | 9 (25.0) | 64(35.8) | 0.214 | 8 (24.2) | 22(28.2) | 0.667 | |
| TACE | 25(69.4) | 104(58.1) | 0.205 | 23(69.7) | 38(48.7) | 0.042 | |
| Ablation | 2(5.6) | 50(27.9) | 0.004 | 2(6.1) | 5(6.4) | 1.000 | |
| Surgical resection | 41(22.9) | 14(38.9) | 0.045 | 14(42.4) | 28(35.9) | 0.517 | |
| HAIC | 9 (25.0) | 36(20.1) | 0.511 | 8 (24.2) | 16(20.5) | 0.663 | |
| Subsequent therapy | |||||||
| Targeted Therapy | 18(50.0) | 137(76.5) | 0.001 | 18(54.5) | 47(60.3) | 0.577 | |
| TACE | 15(41.7) | 28(15.6) | 0.000 | 12(36.4) | 18(23.1) | 0.150 | |
| Ablation | 2(5.6) | 9(5.0) | 1.000 | 2(6.1) | 1(1.3) | 0.210 | |
| HAIC | 5 (13.9) | 30(16.8) | 0.670 | 4 (12.1) | 6(7.7) | 0.480 | |
| AFP (≥400 ug/L) | 16(44.4) | 97(54.2) | 0.285 | 18(54.5) | 35(44.9) | 0.351 | |